M
Matthew C. Cheung
Researcher at Sunnybrook Health Sciences Centre
Publications - 205
Citations - 3405
Matthew C. Cheung is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Population & Rituximab. The author has an hindex of 25, co-authored 199 publications receiving 2418 citations. Previous affiliations of Matthew C. Cheung include Queen Elizabeth II Health Sciences Centre & International Council for the Exploration of the Sea.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes,Laurie H. Sehn,Peter Johnson,Pier Luigi Zinzani,Xiaonan Hong,Jun Zhu,Caterina Patti,David Belada,Olga Samoilova,Cheolwon Suh,Sirpa Leppä,Shinya Rai,Mehmet Turgut,Wojciech Jurczak,Matthew C. Cheung,Ronit Gurion,Ronit Gurion,Su-Peng Yeh,Andres Lopez-Hernandez,Ulrich Dührsen,Catherine Thieblemont,C.S. Chiattone,Sriram Balasubramanian,Jodi Carey,Grace Liu,S. Martin Shreeve,Steven Sun,Sen Hong Zhuang,Jessica Vermeulen,Louis M. Staudt,Wyndham H. Wilson +30 more
TL;DR: The study did not meet its primary end point in the intent-to-treat (ITT) population and the activated B-cell (ABC) DLBCL subgroup, but in patients age younger than 60 years, ibrutinib plus R-CHOP improved EFS, PFS, and OS with manageable safety.
Journal ArticleDOI
AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy
TL;DR: An up-to-date review of the epidemiology, pathogenesis, clinical features, and treatment of various AIDS-related malignancies that are likely to be encountered by an oncologist practicing in the current HAART era is provided.
Journal ArticleDOI
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.
Joseph Mikhael,Nofisat Ismaila,Matthew C. Cheung,Caitlin Costello,Madhav V. Dhodapkar,Shaji Kumar,Martha Q. Lacy,Brea Lipe,Richard F. Little,Anna S. Nikonova,James L. Omel,Namrata Peswani,Anca Prica,Noopur Raje,Rahul Seth,David H. Vesole,David H. Vesole,Irwin Walker,Alexander C Whitley,Tanya M. Wildes,Sandy W. Wong,Thomas Martin +21 more
TL;DR: Evidence-based recommendations were developed for patients with multiple myeloma who are transplantation eligible and those who are ineligible and for Patients with relapsed or refractory disease.
Journal ArticleDOI
First clinical‐grade porcine kidney xenotransplant using a human decedent model
Paige M. Porrett,Babak J. Orandi,Vineeta Kumar,Julie A. Houp,Douglas J. Anderson,A. Cozette Killian,Vera Hauptfeld-Dolejsek,Dominque E Martin,Sara Macedon,Natalie Budd,Katie Stegner,Amy Dandro,Maria Kokkinaki,Kasinath Kuravi,Rhiannon D. Reed,Huma Fatima,John T. Killian,Gavin Baker,Jackson Perry,Emma D. Wright,Matthew C. Cheung,Elise N. Erman,Karl Kraebber,Tracy L. Gamblin,Linda Guy,James N. George,David Ayares,Jayme E. Locke +27 more
TL;DR: The study suggests that major barriers to human xenotransplantation have been surmounted and identifies where new knowledge is needed to optimize xenotranplantation outcomes in humans.
Journal ArticleDOI
Impact of aggressive management and palliative care on cancer costs in the final month of life.
Matthew C. Cheung,Craig C. Earle,Jagadish Rangrej,Thi H. Ho,Ning Liu,Lisa Barbera,Refik Saskin,Joan Porter,Soo Jin Seung,Nicole Mittmann +9 more
TL;DR: A significant share of the cost of cancer care is concentrated in the end‐of‐life period, and quality measures of aggressive treatment may guide optimal care during this timeframe, but little is known about whether these metrics affect costs of care.